sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020

Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020

Home / Categories / Healthcare
Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020
Coronavirus (COVID 19) Vaccine Pipeline...
Report Code
RO1/101/553

Publish Date
30/Apr/2020

Pages
135
PRICE
$ 1290/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 1990/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 1990/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
1. Executive Summary

2. Coronavirus (COVID-19) - Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
2.1 Introduction
2.2 Pathogen Characteristics
2.3 Signs and Symptoms
2.4 Transmission
2.5 Prevention

3. Funding in the Coronavirus (COVID-19) Vaccine Research

4. Vaccines Developed Against MERS-CoV

5. Vaccines Developed Against SARS-CoV

6. Coronavirus (COVID-19) Vaccine Clinical Trial Insights by Phase, Company and Country

7. Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths

8. Major Partnership and Collaboration Deals in the Coronavirus (COVID - 19) Vaccine Market
8.1 Collaboration Deals
8.2 Partnership Deals

9. Key Vaccine Developers Analysis
9.1 University of Oxford
9.1.1 Business Overview
9.1.2 Promising Coronavirus Vaccines in the Clinical Development
9.1.3 Recent Development
9.2 Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
9.2.1 Business Overview
9.2.2 Promising Coronavirus Vaccines in the Clinical Development
9.2.3 Recent Development
9.3 Heat Biologics Inc./University of Miami
9.3.1 Business Overview
9.3.2 Promising Coronavirus Vaccines in the Clinical Development
9.3.3 Recent Development
9.4 Inovio Pharmaceuticals Inc
9.4.1 Business Overview
9.4.2 Promising Coronavirus Vaccines in the Clinical Development
9.4.3 Recent Development
9.5 Janssen Pharmaceutical
9.5.1 Business Overview
9.5.2 Promising Coronavirus Vaccines in the Clinical Development
9.5.3 Recent Development
9.6 Sanofi Pasteur/GlaxoSmithKline (GSK)
9.6.1 Business Overview
9.6.2 Promising Coronavirus Vaccines in the Clinical Development
9.6.3 Recent Development
9.7 Moderna/NIAID
9.7.1 Business Overview
9.7.2 Promising Coronavirus Vaccines in the Clinical Development
9.7.3 Recent Development
9.8 Novavax
9.8.1 Business Overview
9.8.2 Promising Coronavirus Vaccines in the Clinical Development
9.8.3 Recent Development
9.9 Sanofi Pasteur/Translate Bio Inc.
9.9.1 Business Overview
9.9.2 Promising Coronavirus Vaccines in the Clinical Development
9.9.3 Recent Development
9.10 Vaxart Inc.
9.10.1 Business Overview
9.10.2 Promising Coronavirus Vaccines in the Clinical Development
9.10.3 Recent Development
9.11 Altimmune
9.11.1 Business Overview
9.11.2 Promising Coronavirus Vaccines in the Clinical Development
9.11.3 Recent Development
9.12 Medicago
9.12.1 Business Overview
9.12.2 Promising Coronavirus Vaccines in the Clinical Development
9.12.3 Recent Development
9.13 BioNTech/Pfizer/Fosun Pharma
9.13.1 Business Overview
9.13.2 Promising Coronavirus Vaccines in the Clinical Development
9.13.3 Recent Development
9.14 GeoVax/BravoVax
9.14.1 Business Overview
9.14.2 Promising Coronavirus Vaccines in the Clinical Development
9.14.3 Recent Development
9.15 Arcturus Therapeutics/Duke-NUS
9.15.1 Business Overview
9.15.2 Promising Coronavirus Vaccines in the Clinical Development
9.15.3 Recent Development
9.16 CanSino Biological Inc/Beijing Institute of Biotechnology
9.16.1 Business Overview
9.16.2 Promising Coronavirus Vaccines in the Clinical Development
9.16.3 Recent Development
9.17 Takis Biotech/Applied DNA Sciences/Evvivax
9.17.1 Business Overview
9.17.2 Promising Coronavirus Vaccines in the Clinical Development
9.17.3 Recent Development
9.18 Cobra Biologics/Karolinska Institute
9.18.1 Business Overview
9.18.2 Promising Coronavirus Vaccines in the Clinical Development
9.18.3 Recent Development
9.19 Zydus Cadila
9.19.1 Business Overview
9.19.2 Promising Coronavirus Vaccines in the Clinical Development
9.19.3 Recent Development
9.20 Codagenix/Serum Institute of India
9.20.1 Business Overview
9.20.2 Promising Coronavirus Vaccines in the Clinical Development
9.20.3 Recent Development
9.21 Greffex
9.21.1 Business Overview
9.21.2 Promising Coronavirus Vaccines in the Clinical Development
9.21.3 Recent Development
9.22 ExpreS2ion Biotechnologies ApS
9.22.1 Business Overview
9.22.2 Promising Coronavirus Vaccines in the Clinical Development
9.22.3 Recent Development
9.23 Vaxil Bio Therapeutics
9.23.1 Business Overview
9.23.2 Promising Coronavirus Vaccines in the Clinical Development
9.23.3 Recent Development
9.24 Flow Pharma Inc
9.24.1 Business Overview
9.24.2 Promising Coronavirus Vaccines in the Clinical Development
9.24.3 Recent Development
9.25 AJ Vaccines
9.25.1 Business Overview
9.25.2 Promising Coronavirus Vaccines in the Clinical Development
9.25.3 Recent Development
9.26 Generex Biotechnology/EpiVax
9.26.1 Business Overview
9.26.2 Promising Coronavirus Vaccines in the Clinical Development
9.26.3 Recent Development
9.27 Immunomic Therapeutics/EpiVax/PharmaJet
9.27.1 Business Overview
9.27.2 Promising Coronavirus Vaccines in the Clinical Development
9.27.3 Recent Development
9.28 iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
9.28.1 Business Overview
9.28.2 Promising Coronavirus Vaccines in the Clinical Development
9.28.3 Recent Development
9.29 VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
9.29.1 Business Overview
9.29.2 Promising Coronavirus Vaccines in the Clinical Development
9.29.3 Recent Development
9.30 Tonix Pharmaceuticals/Southern Research
9.30.1 Business Overview
9.30.2 Promising Coronavirus Vaccines in the Clinical Development
9.30.3 Recent Development
9.31 IAVI/Batavia Biosciences
9.31.1 Business Overview
9.31.2 Promising Coronavirus Vaccines in the Clinical Development
9.31.3 Recent Development
9.32 Curevac
9.32.1 Business Overview
9.32.2 Promising Coronavirus Vaccines in the Clinical Development
9.32.3 Recent Development
9.33 Imophoron Ltd/University of Bristol
9.33.1 Business Overview
9.33.2 Promising Coronavirus Vaccines in the Clinical Development
9.33.3 Recent Development
9.34 BioNet Asia
9.34.1 Business Overview
9.34.2 Promising Coronavirus Vaccines in the Clinical Development
9.34.3 Recent Development
9.35 Sinovac/Dynavax
9.35.1 Business Overview
9.35.2 Promising Coronavirus Vaccines in the Clinical Development
9.35.3 Recent Development
9.36 BIOCAD
9.36.1 Business Overview
9.36.2 Promising Coronavirus Vaccines in the Clinical Development
9.36.3 Recent Development
9.37 University of Pittsburgh
9.37.1 Business Overview
9.37.2 Promising Coronavirus Vaccines in the Clinical Development
9.37.3 Recent Development

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com